Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

System for time-discretized vacuum ultraviolet spectroscopy of spark breakdown in air.

Ryberg D, Fierro A, Dickens J, Neuber A.

Rev Sci Instrum. 2014 Oct;85(10):103109. doi: 10.1063/1.4897295.

PMID:
25362373
2.

Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Langevin SM, Ioannidis JP, Vineis P, Taioli E; Genetic Susceptibility to Environmental Carcinogens group (GSEC).

Pharmacogenet Genomics. 2010 Oct;20(10):586-97. doi: 10.1097/FPC.0b013e32833c3892.

3.

The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung.

Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, Houlston R, Haugen A.

Carcinogenesis. 2009 Aug;30(8):1368-71. doi: 10.1093/carcin/bgp131. Epub 2009 May 22.

PMID:
19465454
4.

A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, Canzian F, Haugen A.

Carcinogenesis. 2008 Jun;29(6):1164-9. doi: 10.1093/carcin/bgn020. Epub 2008 Feb 6.

PMID:
18258609
5.

Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.

Lind H, Ekstrøm PO, Ryberg D, Skaug V, Andreassen T, Stangeland L, Haugen A, Zienolddiny S.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2077-81.

6.

Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer.

Campa D, Zienolddiny S, Lind H, Ryberg D, Skaug V, Canzian F, Haugen A.

Lung Cancer. 2007 Apr;56(1):17-23. Epub 2006 Dec 18.

PMID:
17175058
7.

Msh2 deficiency increases susceptibility to benzo[a]pyrene-induced lymphomagenesis.

Zienolddiny S, Ryberg D, Svendsrud DH, Eilertsen E, Skaug V, Hewer A, Phillips DH, te Riele H, Haugen A.

Int J Cancer. 2006 Jun 1;118(11):2899-902.

8.

Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, Phillips DH, Canzian F, Haugen A.

Carcinogenesis. 2006 Mar;27(3):560-7. Epub 2005 Sep 29.

PMID:
16195237
9.

Chromosome aberrations in tunnel workers exposed to acrylamide and N-methylolacrylamide.

Kjuus H, Hansteen IL, Ryberg D, Goffeng LO, Ovrebø S, Skaug V.

Scand J Work Environ Health. 2005 Aug;31(4):300-6.

10.

Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene.

Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A.

Lung Cancer. 2005 Dec;50(3):285-90. Epub 2005 Aug 26.

PMID:
16126303
11.

Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study.

Raimondi S, Boffetta P, Anttila S, Bröckmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dragani TA, Garte S, Gsur A, Haidinger G, Hirvonen A, Ingelman-Sundberg M, Kalina I, Lan Q, Leoni VP, Le Marchand L, London SJ, Neri M, Povey AC, Rannug A, Reszka E, Ryberg D, Risch A, Romkes M, Ruano-Ravina A, Schoket B, Spinola M, Sugimura H, Wu X, Taioli E.

Mutat Res. 2005 Dec 30;592(1-2):45-57. Epub 2005 Jul 11.

PMID:
16009381
12.

Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway.

Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, Ryberg D, Haugen A, Olsen JH.

Lung Cancer. 2005 May;48(2):187-99. Epub 2004 Dec 15.

PMID:
15829318
13.

CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions.

Vineis P, Veglia F, Anttila S, Benhamou S, Clapper ML, Dolzan V, Ryberg D, Hirvonen A, Kremers P, Le Marchand L, Pastorelli R, Rannug A, Romkes M, Schoket B, Strange RC, Garte S, Taioli E.

Biomarkers. 2004 May-Jun;9(3):298-305.

PMID:
15764294
14.

Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer.

Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A.

Int J Cancer. 2004 Apr 10;109(3):353-6.

15.

Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States).

Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stücker I, Sugimura H, Taioli E.

Cancer Causes Control. 2003 May;14(4):339-46.

PMID:
12846365
16.

Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk.

Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, Brockmöller J, Clapper ML, Daly A, Dolzan V, Ford J, Gaspari L, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Ingelman-Sundberg M, Kalina I, Kihara M, Kremers P, Le Marchand L, London SJ, Nazar-Stewart V, Onon-Kihara M, Rannug A, Romkes M, Ryberg D, Seidegard J, Shields P, Strange RC, Stücker I, To-Figueras J, Brennan P, Taioli E.

Carcinogenesis. 2002 Aug;23(8):1343-50. Erratum in: Carcinogenesis 2002 Oct;23(10):1771.

PMID:
12151353
17.

Metabolic gene polymorphism frequencies in control populations.

Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stücker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48.

18.

Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.

Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC.

Cancer Res. 2001 Sep 1;61(17):6350-5.

19.

Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.

Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A.

Br J Cancer. 2001 Jan;84(2):226-31.

20.

Induction of microsatellite mutations by oxidative agents in human lung cancer cell lines.

Zienolddiny S, Ryberg D, Haugen A.

Carcinogenesis. 2000 Aug;21(8):1521-6.

PMID:
10910953

Supplemental Content

Loading ...
Support Center